Compounds > reumycin
Page last updated: 2024-11-11

reumycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

reumycin: isolated from Actinomyces; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

reumycin : A pyrimidotriazine that is 6-methyl-5,6,7,8-tetrahydropyrimido[5,4-e][1,2,4]triazine with oxo groups at positions 5 and 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5351216
CHEMBL ID1703515
CHEBI ID121196
SCHEMBL ID3231479
MeSH IDM0053642

Synonyms (52)

Synonym
MLS001048964 ,
smr000008544
pyrimido(5,4-e)-as-triazine-5,7(6h,8h)-dione, 6-methyl-
1-demethyltoxoflavine
pyrimido(5,4-e)-as-triazine-5,7(1h,6h)-dione, 6-methyl-
nsc 99733
rheumycin
n-1-demethylxanthotricin
6-methylpyrimido(5,4-e)-as-triazine-5,7(1h,6h)-dione
ba 51-090492
6-methyl-8h-pyrimido[5,4-e][1,2,4]triazine-5,7-dione
NCIMECH_000143
NCI60_042239
6-methyl-1h-pyrimido[5,4-e][1,2,4]triazine-5,7-dione
6-methylpyrimido[5,4-e][1,2,4]triazine-5,7(1h,6h)-dione
pyrimido[5,7(6h,8h)-dione, 6-methyl-
nsc99733 ,
nsc-99733
rheumygin
reumycin
5016-18-2
reumitsin
STK177195
6-methylpyrimido[5,4-e][1,2,4]triazine-5,7(6h,8h)-dione
reumicine
6-methyl-pyrimido-[5,4-e]-as-triazine-5,7(6h,8h)-dione
1-demethyltoxoflavin
CHEBI:121196
VU0419388-1
HMS1610C13
AKOS001632553
AKOS006275055
CCG-35339
n94s395mfa ,
unii-n94s395mfa
HMS2754A09
ZLLAXLPOOMLVRF-UHFFFAOYSA-N
SCHEMBL3231479
CHEMBL1703515
6-methyl-8h-pyrimido[5,4-e][1,2,4]triazine-5,7-quinone
bdbm83941
cid_5351216
az9 ,
DTXSID90198223
Q9068429
6-methylpyrimido(5,4-e)-1,2,4-triazine-5,7(6h,8h)-dione
pyrimido(5,4-e)-1,2,4-triazine-5,7(6h,8h)-dione, 6-methyl-
1,5,6,7-tetrahydro-6-methylpyrimidino-(5,4-e)triazine-5,7-dione
BCP31999
rheumygin;1-demethyltoxoflavine
C21957
PD011796

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Intracerebrally and suboccipitally injected variamycin and mitramycin induced marked toxic reactions, even the death of animals, and cannot be recommended for the neurooncological clinic."( [Toxicity of anti-tumor preparations after intracranial, subarachnoid and suboccipital administration (experimental study)].
Annin, EA; Egorenko, GG; Romodanov, SA; Semenova, VM; Verkhogliadova, TP, )		0.13

Pharmacokinetics

The value of the reumycin half-life in humans was predicted (41-46 hours) The dose dependence of the pharmacokinetic parameters and in the particular of the area under the reumsycin blood concentration on the time curve varied with patients.

ExcerptReferenceRelevance
" The value of the reumycin half-life in humans was predicted (41-46 hours) with the pharmacokinetic animal scale-up."( [Pharmacokinetics of the new antitumor antibiotic reumycin in an experiment: the prediction of the human pharmacokinetic profiles].
Firsov, AA; Fomina, IP; Geodakian, SV; Terent'eva, TG, 1985)		0.86
" The dose dependence of the pharmacokinetic parameters and in the particular of the area under the reumycin blood concentration on the time curve and cumulative renal excretion varied with patients."( [Clinical pharmacokinetics of the antitumor antibiotic reumycin: an analysis of individual variability].
Firsov, AA; Geodakian, SV; Lichinitser, MR; Shutka, VIa, 1985)		0.73

Bioavailability

ExcerptReferenceRelevance
" The absolute extent of the reumycin bioavailability after oral administration was 50 per cent."( [Pharmacokinetics of the new antitumor antibiotic reumycin in an experiment: the prediction of the human pharmacokinetic profiles].
Firsov, AA; Fomina, IP; Geodakian, SV; Terent'eva, TG, 1985)		0.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyrimidotriazineAny organic heterobicyclic compound containing ortho-fused pyrimidine and triazine rings.
carbonyl compoundAny compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
toxoflavin biosynthesis318

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency19.95260.631035.7641100.0000AID504339
USP1 protein, partialHomo sapiens (human)Potency14.12540.031637.5844354.8130AID743255
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Apoptotic peptidase activating factor 1Homo sapiens (human)IC50 (µMol)57.70000.037518.623253.2000AID588524; AID588538
caspase-9 isoform alpha precursorHomo sapiens (human)IC50 (µMol)11.40000.025616.507052.8000AID588574
caspase-3 isoform a preproproteinHomo sapiens (human)IC50 (µMol)11.40000.025620.323574.3000AID588574
sentrin-specific protease 8Homo sapiens (human)IC50 (µMol)1.85000.040818.929294.8000AID624322; AID651559
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Caspase 6, apoptosis-related cysteine peptidaseHomo sapiens (human)AC507.06000.063611.235844.9700AID720632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (53.33)18.7374
1990's0 (0.00)18.2507
2000's1 (6.67)29.6817
2010's5 (33.33)24.3611
2020's1 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.11 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
sisomicin
Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).		1.9610amino cyclitol glycoside;
aminoglycoside antibiotic;
beta-L-arabinoside;
monosaccharide derivative
toxoflavin
toxoflavin: azapteridine antibiotic; structure. toxoflavin : A pyrimidotriazine that is 1,6-dimethyl-1,5,6,7-tetrahydropyrimido[5,4-e][1,2,4]triazine with oxo groups at positions 5 and 7.		7.4120carbonyl compound;
pyrimidotriazine		antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
toxin;
virulence factor;
Wnt signalling inhibitor
fervenulin
fervenulin: structure		7.4120
pyrimidinones
Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.		2.4120
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		01.9510
Benign Neoplasms, Brain
[description not available]		01.9610
Cancer of Kidney
[description not available]		01.9610
Metastase
[description not available]		01.9610
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		01.9610
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		01.9610
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		01.9610